Table 1.

Antifungal effect of chalcone-based analogues 1–40 against C. albicans control strain.

Compound	Structure	Inhibition (%) [at 100 μM]	IC50 [μM] a,b	IC50 [μg/mL] a,b
1		65.2 ± 3.9	52.8 [44.6–62.6]	13.7 [11.5–16.2]
2		35.8 ± 1.1	n.d.	n.d.
3		64.8 ± 1.5	57.7 [47.1–70.8]	16.0 [13.0–19.6]
4		65.6 ± 3.3	48.9 [41.9–57.0]	13.5 [11.6–15.8]
5		62.0 ± 1.5	51.3 [41.3–63.8]	15.1 [12.2–18.8]
6		<1	n.d.	n.d.
7		69.0 ± 12.4	53.0 [43.8–64.0]	13.8 [11.4–16.7]
8		<1	n.d.	n.d.
9		38.5 ± 2.9	n.d.	n.d.
10 c		23.3 ± 9.6	n.d.	n.d.
11		9.8 ± 6.7	n.d.	n.d.
12 c		>99	30.7 [27.0–35.0]	9.0 [7.9–10.3].
13 c		>99	8.1 [6.8–9.6]	2.4 [2.0–2.8]
14 c		63.6 ± 6.8	39.2 [26.8–57.4]	11.5 [7.9–16.8]
15		<1	n.d.	n.d.
16 c		91.9 ± 8.2	10.8 [9.3–12.5]	3.2 [2.7–3.7]
17		11.0 ± 3.9	n.d.	n.d.
18 c		34.1 ± 7.5	n.d.	n.d.
19		5.9 ± 5.7	n.d.	n.d.
20 c		81.5 ± 4.7	16.8 [13.6–20.6]	4.9 [4.0–6.0]
21 c		96.5 ± 1.4	12.6 [10.6–15.1]	3.7 [3.1–4.4]
22 c		<1	n.d.	n.d.
23		4.6 ± 13.8	n.d.	n.d.
24 c		72.0 ± 9.8	43.8 [30.6–62.7]	12.8 [9.0–18.4]
25 c		81.3 ± 17.0	26.3 [19.6–35.4]	7.7 [5.7–10.4]
26 c		63.9 ± 3.4	36.8 [29.2–46.3]	10.8 [8.6–13.6]
27		<1	n.d.	n.d.
28		99.1 ± 0.7	55.9 [50.9–61.3]	27.7 [25.2–30.4]
29		17.8 ± 4.1	n.d.	n.d.
30		9.5 ± 4.8	n.d.	n.d.
31		97.3 ± 0.5	12.0 [9.3–15.6]	3.5 [2.7–4.6]
32		<1	n.d.	n.d.
33		<1	n.d.	n.d.
34		37.9 ± 5.2	n.d.	n.d.
35		13.9 ± 3.6	n.d.	n.d.
36		<1	n.d.	n.d.
37		<1	n.d.	n.d.
38		46.3 ± 3.7	n.d.	n.d.
39		<1	n.d.	n.d.
40		<1	n.d.	n.d.
Licochalcone d			62.5–150	18.3–44.0
FLC		n.d.	0.25 [0.18–0.33]	0.07 [0.05–0.1]

^a IC₅₀ is defined as the concentration giving rise to an inhibition of growth of 50% compared to the drug-free control. ^b Data are reported as mean values and 95% confidence interval. ^c See [17]. ^d See [16], FLC, fluoconazole; n.d., not determined.